Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have earned an average rating of “Buy” from the six analysts that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $9.80.

Several equities analysts have recently issued reports on the company. Leerink Partners lifted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Finally, JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th.

Aquestive Therapeutics Stock Down 5.5 %

AQST opened at $4.81 on Tuesday. The stock has a market capitalization of $438.58 million, a price-to-earnings ratio of -10.69 and a beta of 2.82. Aquestive Therapeutics has a twelve month low of $1.84 and a twelve month high of $6.23. The company has a 50-day simple moving average of $4.99 and a 200 day simple moving average of $4.00.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period in the previous year, the business posted ($0.03) earnings per share. Sell-side analysts anticipate that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after buying an additional 1,353,518 shares during the period. Geode Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 5.7% in the third quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after purchasing an additional 90,543 shares during the last quarter. State Street Corp grew its stake in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Blue Owl Capital Holdings LP increased its holdings in Aquestive Therapeutics by 30.3% in the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares during the period. Finally, Janney Montgomery Scott LLC raised its position in Aquestive Therapeutics by 4.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock worth $4,598,000 after purchasing an additional 42,800 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.